Advanced searches left 3/3

Cardiotoxicity Cancer Patients - Europe PMC

Summarized by Plex Scholar
Last Updated: 03 September 2022

* If you want to update the article please login/register

Cardiotoxicity among socioeconomically marginalized breast cancer patients.

We also attempted to determine cardiotoxicity risk among socioeconomically marginalized breast cancer patients treated with anthracyclines or trastuzumab, as well as the clinical implications of cardiotoxicity. Methods We compared electronic health data from a Comprehensive Community Cancer Program within a safety-net health framework with institutional registry data from a Comprehensive Community Cancer Program within a safety-net health framework. The findings of our study included 169 women with breast cancer. In women who began trastuzumab, the risk of cardiotoxicity was 21% at one year and 25 percent at three years, while cumulative incidence was 5. 9% at one year and 5. 9% at three years, respectively. Conclusion After the introduction of anthracyclines or trastuzumab, socioeconomically marginalized breast cancer patients, we found a higher risk of cardiotoxicity among socioeconomically marginalized breast cancer patients.

Source link: https://europepmc.org/article/MED/35971056


Biomarker panel for early screening of trastuzumab -induced cardiotoxicity among breast cancer patients in west virginia.

Cardiotoxicity is a well-known pathophysiological response in breast cancer patients receiving trastuzumab. Trastuzumab-related cardiotoxicity is typical of a general decline in cardiac function, primarily due to the decrease in left ventricular ejection fraction and the occurrence of heart failure-related symptoms. Patients with clinical diagnosis of invasive ductal carcinoma were included in the research, with blood test and echocardiography performed before trastuzumab therapy implementation at baseline, 3-, and 6-months post trastuzumab therapy. The results in the present study show that the translated biomarker and circulating miRNAs were highly correlated with the cardiac injury specific indicators, troponin I and T. The results show that the proposed biomarker panel in early preclinical diagnosis of trastuzumab-induced cardiotoxicity, allowing earlier detection of heart disease prevention and improved breast cancer survival in breast cancer patients.

Source link: https://europepmc.org/article/MED/36034829


Cardioprotective Strategies from Cardiotoxicity in Cancer Patients: A Comprehensive Review.

Cardiotoxicity is a common complication of chemotherapy-mediated agents in cancer patients. LV dysfunction, heart disease, acute arrhythmias, arterial hypertension, arterial hypertension, and death are all related to elevated morbidity and mortality in cardiovascular conditions. Particularly in high-risk patients for cardiotoxicity, risk stratification of cancer patients prior to chemotherapy is critical. Cardiotoxicity prevention or minimization of cardiovascular disease can be aided by the early detection and monitoring of potential risk factors for cardiovascular side effects. Patients with cancer patients receiving chemotherapy may benefit from collaborative oncologists, cardiologists, and cardiologists.

Source link: https://europepmc.org/article/MED/36005423


Grading Evaluation of Cardiotoxicity in Patients with Breast Cancer Treated with Adjuvant Paclitaxel Anthracycline/Cyclophosphamide Chemotherapy: A Meta-Analysis.

The heart safety of concurrent treatment with anthracycline, cyclophosphamide, and paclitaxel in an adjuvant BC treatment regimen is also questionable. We wanted to determine cardiotoxicity in this research among ACT chemotherapy recipients with HER2-positive breast cancer patients. Methods We searched PubMed and the Cochrane Library for RCTs prior to July 2019 reviewing the cardiac risk of ACT chemotherapy regimens in BC patients. Conclusions The ACT treatment in patients with HER2-negative BC was attributed to an elevated risk of adverse cardiac toxic events.

Source link: https://europepmc.org/article/MED/35979049

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions